RDT helps bring orphan drugs to market by partnering with companies to provide life-saving therapies for patients with rare diseases.
With over 30 years of experience in orphan drug commercialization, including experience in antivenoms, oncology, hematology, metabolic diseases, and genetic disorders, RDT maintains a foundational presence in rare disease outreach.
ANTIVENOM—FDA-APPROVED PRODUCTS
Name
Status
Links
ANTIVENOM—FDA-APPROVED PRODUCTS
Name
Status
Available
Links
Name
Status
Available
Links
HEMATOLOGY/ONCOLOGY—FDA-APPROVED PRODUCTS
Name
Status
Links
HEMATOLOGY/ONCOLOGY—FDA-APPROVED PRODUCTS
Name
Status
AVAILABLE
Links
HEMATOLOGY/ONCOLOGY—RESEARCH PRODUCTS
Name
Status
Links
To report a suspected adverse reaction or to order any of our approved products, please call 1-844-472-7389.
If you prefer to report adverse reactions to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
HEMATOLOGY/ONCOLOGY—Research products
Name
Status
NDA Pending
Links
To report a suspected adverse reaction or to order any of our approved products, please call 1-844-472-7389.
If you prefer to report adverse reactions to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Reference:
1. McKiernan PJ (2006). “Nitisinone in the treatment of hereditary tyrosinaemia type 1”. Drugs. 66 (6): 743–750.